A new study reports that people who stop taking GLP-1 drugs like Ozempic may lose heart protection fast, and restarting the drug later may not bring all of it back.

GLP-1 drugs are medicines that help control blood sugar and often lead to weight loss. Ozempic is one well-known brand. Here, we break down what the numbers in this study actually mean, because nobody should need a dictionary to follow health news like this.

The study looked at how long people stayed on GLP-1 treatment and what happened to their heart risk when they stopped. People who stayed on the drug for two years before stopping still had a 7% drop in cardiovascular risk by the end of the study. Those who stayed on for two and a half years saw a 15% drop.

But people who quit before 18 months showed no real drop in heart risk at all, compared with people taking a different diabetes drug called sulfonylureas.

Gaps in treatment hurt the most

Taking a break from the drug and then going back on it also weakened the benefit. People who stayed on GLP-1 drugs for three straight years had an 18% drop in risk. People who paused and then restarted only saw a 12% drop on average.

Even a six-month break was enough to cause harm. Compared with staying on the drug the whole time, these gaps raised heart risk by 4% to 8%.

Longer breaks made things worse. A full year off the drug, with no restart, raised risk by 14% compared with staying on it the whole time. Two years off raised that number to 22%.

What this means for you

1. If you take a GLP-1 drug for your heart, staying on it without breaks matters a lot.
2. A short pause, even six months, can undo some of the protection you built up.
3. Restarting the drug helps, but the study found it does not fully restore what was lost.

Study author Ziyad Al-Aly said doctors should treat staying on the medicine as a real goal, not an afterthought. He said health systems need plans to help people keep taking these drugs for the long run. That includes managing side effects, being honest that treatment may be lifelong, and helping with the cost of the drugs, since price often causes people to stop.

Al-Aly also pointed out that heart benefits build up slowly over time but can disappear quickly once someone stops.

The study was funded by the U.S. Department of Veterans Affairs. The funders had no say in how the study was designed, run, or written up.

If you take a GLP-1 drug, talk to your doctor before pausing it, even for a short time.